Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.
Accuray Incorporated (NASDAQ: ARAY) generates a steady flow of news related to radiation oncology, product innovation, clinical collaborations and corporate strategy. As a developer and manufacturer of radiation therapy systems such as the CyberKnife System and the Radixact Treatment Delivery System, the company regularly issues updates on technology launches, clinical milestones and organizational changes that are relevant to investors, clinicians and other stakeholders following ARAY stock.
News about Accuray often highlights advances in its radiation therapy portfolio. Recent announcements have included the introduction of the Accuray Stellar Solution, a configuration of the Radixact system initially for the U.S. market, designed to support adaptive radiotherapy and multiple delivery modalities. The company also reports on collaborations, such as a memorandum of understanding with the University of Wisconsin School of Medicine and Public Health to advance online adaptive radiotherapy on its helical radiation treatment delivery platform.
Corporate and financial developments are another key focus of Accuray’s news flow. Press releases and related SEC filings cover quarterly and annual financial results, guidance, non-GAAP measures such as adjusted EBITDA, and details of a comprehensive strategic, operational and organizational transformation plan. These communications describe initiatives such as streamlining the commercial structure, centralizing core functions, outsourcing selected non-core activities, and workforce reductions, along with associated restructuring charges and expected effects on operating profitability.
Governance and capital structure updates also appear in the company’s news. Examples include leadership changes, board appointments, equity incentive plans, and financing agreement amendments that involve warrants to purchase common stock. Clinical and market expansion stories, such as the first CyberKnife S7 System treatments in Melbourne, Australia through a collaboration with 5D Clinics and Icon Group, illustrate how Accuray’s technology is being deployed in new locations and settings.
This ARAY news page brings together these types of announcements in one place, allowing readers to review product launches, clinical collaborations, financial disclosures and transformation updates over time. For anyone researching Accuray’s business direction, technology focus or corporate actions, the news feed offers a structured view of the company’s public communications.
Accuray Incorporated (NASDAQ: ARAY) has appointed Franco N. Palomba as the new vice president, chief accounting officer & controller effective June 15, 2022. With over 30 years of expertise in accounting and finance, primarily in the radiation therapy sector, Palomba's role will encompass the global accounting organization and compliance operations. He previously held significant positions at Varian Medical Systems and Ashvattha Therapeutics. Palomba aims to drive growth and enhance shareholder value, emphasizing the importance of innovation in radiation therapy.
Accuray Incorporated (NASDAQ: ARAY) announced the granting of equity inducement awards to Sandeep Chalke, its new senior vice president and chief commercial officer, as per NASDAQ Listing Rules. The awards include 312,500 restricted stock units and a stock option for 515,873 shares, effective May 31, 2022. The stock options have a ten-year term with an exercise price of $2.08 per share. Vesting for both awards is contingent on Mr. Chalke’s continued service, with 25% vesting annually for restricted stock units and monthly increments for the stock options.
Accuray Incorporated (NASDAQ: ARAY) has announced a partnership with Limbus AI Inc. to enhance adaptive radiotherapy capabilities through AI-driven autocontouring algorithms. This collaboration aims to automate the contouring process, which is vital for efficient treatment planning, allowing for quicker adaptations in response to changes in tumor size and location. The integrated solution is expected to launch in 2023, promoting operational efficiency for medical teams and improving patient care.
Accuray (NASDAQ: ARAY) has appointed Sandeep Chalke as Senior Vice President and Chief Commercial Officer effective May 16, 2022. Chalke brings over 25 years of medical device experience, having previously served at Vyaire Medical, where he managed P&L across Asia-Pacific and Latin America. His expertise includes commercialization and market expansion. Suzanne Winter, President of Accuray, expressed confidence in Chalke's ability to enhance customer centricity and accelerate commercialization strategies, aimed at improving access to cancer treatment solutions.
Accuray Incorporated (NASDAQ: ARAY) reported on new clinical studies presented at the ESTRO 2022 congress, illustrating the effectiveness of its CyberKnife® and TomoTherapy® platforms. These technologies support personalized cancer treatment across various complexities. Key findings reveal the CyberKnife platform's robotic capabilities enhance treatment precision, while TomoTherapy optimizes radiation delivery. Notable advancements include improved therapy for breast cancer and neurologic disorders. Accuray emphasizes its commitment to innovation and partnerships that bolster its product effectiveness for patient care.
Summary not available.
Accuray reported its third-quarter fiscal 2022 results, showing gross orders of $88.6 million, a 1% increase year-over-year. However, net revenue fell 6% to $96.2 million. The company incurred a GAAP net loss of $1.0 million, worsening from a loss of $0.4 million the prior year. Adjusted EBITDA dropped to $5.4 million from $8.7 million. While product revenue increased by 30% over nine months, service revenue saw a 1% decline. Operational challenges persist due to supply chain issues attributed to COVID-19.
Accuray announced Suzanne Winter as its new CEO, effective July 1, 2022, succeeding Joshua Levine who will retire from the Board on June 30, 2022. Winter, who joined Accuray in 2019 and has led significant operational strategies, aims to enhance patient care and innovation in radiation therapy. Ali Pervaiz has been appointed as CFO, effective May 9, 2022, bringing extensive financial leadership experience from GE Healthcare. The leadership transition aims to build on the company's recent growth and strengthen shareholder value.
In April 2022, Al Gold, owner of Arkansas Derby winner Cyberknife, shared his journey with prostate cancer and praised the Accuray CyberKnife System for its non-invasive treatment. His successful treatment enabled him to enjoy family activities and celebrate his horse's victory. Gold's positive experience highlights CyberKnife's precision in targeting tumors while minimizing damage to surrounding tissues, a key advantage for prostate cancer patients. Accuray emphasizes the technology's effectiveness, supported by clinical evidence, as it continues to innovate in radiation therapy.
Accuray Incorporated (NASDAQ: ARAY) will release its financial results for the third quarter of fiscal year 2022, covering the period ending March 31, 2022, on April 27, 2022. A conference call to discuss these results will take place at 1:30 PM PT / 4:30 PM ET on the same day. Interested parties can join via dial-in numbers or listen to a live webcast through the company's Investor Relations website. The replay will be available shortly after the call for one week.